Bani Azari, MD
Cardiovascular Disease · Manhasset, NYNPI 1659667855
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,006 of the $3,927 with a category attached, or 76.5%. Sanofi accounts for 79.2% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2022 at $3,172 and has fallen 93.9% since, to $192 in 2025.
Across 15 payments — averaging $261.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$3K
- Alnylam Pharmaceuticals Inc.$198
- Amarin Pharma, Inc.$125
- E.r. Squibb & Sons, L.L.C.$125
- Akcea Therapeutics, Inc.$125
- Lantheus Medical Imaging, Inc.$114
- plus $131 from 3 others
What the payments were for
- Speaking & faculty fees$3,00677%
- Food & beverage$92123%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 2 | $3,108 |
| Alnylam Pharmaceuticals Inc. | 2 | $198 |
| Amarin Pharma, Inc. | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Akcea Therapeutics, Inc. | 1 | $125 |
| Lantheus Medical Imaging, Inc. | 4 | $114 |
| Pfizer | 2 | $75 |
| Boehringer Ingelheim | 1 | $40 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,927 in reported general payments places this provider in the 65th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amlodipine Besylate | 13 | $69 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Manhasset
- Bruce RutkinManhasset$267K
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
- Megha PrasadNew York$813K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.